This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
This study is an electronically delivered, one time cross sectional survey study. The investigators want to understand how patients with triple negative breast cancer at high risk for disease recurrence will prioritize additional benefit over toxicity when considering treatment options, and if their knowledge of ctDNA positivity versus negativity will further shift this balance toward benefit.
Study Type
OBSERVATIONAL
Enrollment
289
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Examine whether knowledge of ctDNA negativity influences patient decision-making
Ratings- based analysis will be used to examine whether knowledge of ctDNA negativity increases patient acceptability (and if so, by how much) of no therapy in the adjuvant setting, compared to standard of care capecitabine.
Time frame: Once all surveys in the sample size are completed, 6 months anticipated
Estimate at what degree of benefit a given treatment would be acceptable to patients
When assuming risk of recurrence of ctDNA positivity, we will use ratings- based conjoint analysis to determine part-worth utilities of each attribute - potential toxicity and potential benefit. Comparison of part-worth utilities will be used to estimate at what degree of benefit a given treatment would be acceptable, which will inform future trials.
Time frame: Once all surveys in the sample size are completed, 6 months anticipated
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.